Latest:
Dr. Blum on the Current Treatment Landscape of Acute Myeloid Leukemia
William G. Blum, MD, discusses the current treatment landscape of acute myeloid leukemia.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
William G Wierda, MD, University of Texas MD Anderson Cancer Center
Latest:
Rapid Readouts: Phase 1 Cohort of TRANSCEND-CLL-004 Study
William G. Wierda, MD, discusses data from the phase 1 cohort of lisocabtagene maraleucel combined with ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic leukemia that was presented at the 19th International Workshop on CLL (iwCLL) held in September 2021.
William Kevin Kelly, DO
Latest:
Dr. Kelly on Radium-223 Dichloride and Niraparib in Patients With mCRPC
William K. Kelly, DO, discusses results from a phase 1b dose-finding study (NCT03076203) evaluating the combination of radium-223 dichloride (Xofigo) plus niraparib (Zejula) in patients with metastatic castration-resistant prostate cancer.
William M. Grady, MD
Latest:
Dr. Grady on Gene Profiling of CTCs in Pancreatic Cancer
William M. Grady, MD, from the Fred Hutchinson Cancer Research Center, discusses results from an ongoing prospective study looking at gene expression profiling of circulating tumor cells in patients with unresectable pancreatic cancer.
William K. Oh, MD
William K. Oh, MD, is the director of Precision Medicine at the Yale Cancer Center and Smilow Cancer Hospital, and service line medical director at the Smilow Cancer Hospital, Greenwich Hospital.
Latest:
Dr Oh on the Development of Targeted Therapies in Prostate Cancer
William K. Oh, MD, highlights the evolution of targeted therapy for prostate cancer treatment, including antibody-drug conjugates and bispecific antibodies.